Race Oncology Ltd (ASX:RAC) chief scientific officer Dr Daniel Tillett speaks with Proactive soon after receiving confidential and constructive guidance during a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for its asset Zantrene (bisantrene dihydrochloride). An IND is the prerequisite to clinical trials in the United States and a key step in the process of obtaining a new drug application (NDA) and marketing approval for a new drug.
Race Oncology welcomes positive pre-IND meeting for Zantrene
